Back to Feed
总结
英国媒体报道，英格兰NHS将扩大前列腺癌药物阿比特龙（abiraterone）的可及性，使数千名男性患者可在公费体系内获得这种延长生存期的治疗。该药因仿制药价格较低（报道提及约2.50英镑），被认为具备较高成本效益。政策调整旨在让更多符合条件的患者更早或更广泛地使用药物，预计可延长生命并减少疾病负担，同时对NHS药费支出与用药管理产生影响。
正文
Prostate drug, abiraterone, to be offered to thousands in England BBC NHS expands access to prostate cancer drug in England to save thousands of lives The Guardian Drug costing just £2.50 will extend life of prostate cancer patients The Times Thousands of men to receive prostate cancer drug on NHS The Telegraph Life-extending prostate cancer drug to be made available to thousands more patients The Independent
发布时间：